NYSE:CI - CIGNA Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $172.35 -0.74 (-0.43 %) (As of 07/16/2018 04:00 PM ET)Previous Close$173.09Today's Range$172.27 - $173.3052-Week Range$163.02 - $227.13Volume1.45 million shsAverage Volume2.13 million shsMarket Capitalization$42.11 billionP/E Ratio16.48Dividend Yield0.02%Beta0.62 Company ProfileFinancialsAnalyst RatingsDividend HistoryEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cigna Corporation, a health services organization, provides insurance and related products and services in the United States and internationally. It operates through Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations segments. The Global Health Care segment offers medical, dental, behavioral health, vision, and prescription drug benefit plans, as well as health advocacy programs, and other products and services to insured and self-insured customers. This segment also provides Medicare Advantage and Medicare Part D plans to seniors, and Medicaid plans. The Global Supplemental Benefits segment offers supplemental health, life, and accident insurance products. The Group Disability and Life segment provides group long-term and short-term disability, group life, accident, and specialty insurance products and related services. The Other Operations segment offers corporate-owned life insurance products that are permanent insurance contracts sold to corporations to provide coverage; and run-off settlement annuity contracts. The company distributes its products and services through insurance brokers and insurance consultants; and directly to employers, unions and other groups, or individuals, as well as through direct response television and the Internet. Cigna Corporation was founded in 1792 and is headquartered in Bloomfield, Connecticut. Receive CI News and Ratings via Email Sign-up to receive the latest news and ratings for CI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Hospital & medical service plans Sub-IndustryManaged Health Care SectorFinance SymbolNYSE:CI CUSIP12550910 Webwww.cigna.com Phone860-226-6000 Debt Debt-to-Equity Ratio0.37 Current Ratio0.35 Quick Ratio0.35 Price-To-Earnings Trailing P/E Ratio16.48 Forward P/E Ratio13.02 P/E Growth1.08 Sales & Book Value Annual Sales$41.62 billion Price / Sales1.01 Cash Flow$13.0568 per share Price / Cash13.20 Book Value$55.71 per share Price / Book3.09 Profitability EPS (Most Recent Fiscal Year)$10.46 Net Income$2.24 billion Net Margins5.99% Return on Equity20.90% Return on Assets4.76% Miscellaneous Employees46,000 Outstanding Shares243,270,000Market Cap$42,107.26 CIGNA (NYSE:CI) Frequently Asked Questions What is CIGNA's stock symbol? CIGNA trades on the New York Stock Exchange (NYSE) under the ticker symbol "CI." How often does CIGNA pay dividends? What is the dividend yield for CIGNA? CIGNA declared a quarterly dividend on Wednesday, February 28th. Shareholders of record on Monday, March 12th will be paid a dividend of $0.04 per share on Tuesday, April 10th. This represents a $0.16 annualized dividend and a yield of 0.09%. The ex-dividend date is Friday, March 9th. View CIGNA's Dividend History. How will CIGNA's stock buyback program work? CIGNA announced that its board has approved a share repurchase program on Sunday, June 4th 2017, which permits the company to repurchase $3,700,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy up to 9.8% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company's board of directors believes its stock is undervalued. How were CIGNA's earnings last quarter? CIGNA Co. (NYSE:CI) issued its earnings results on Thursday, May, 3rd. The health services provider reported $4.11 EPS for the quarter, topping the Zacks' consensus estimate of $3.39 by $0.72. The health services provider earned $11.38 billion during the quarter, compared to analysts' expectations of $10.97 billion. CIGNA had a return on equity of 20.90% and a net margin of 5.99%. The company's revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.77 earnings per share. View CIGNA's Earnings History. When is CIGNA's next earnings date? CIGNA is scheduled to release their next quarterly earnings announcement on Thursday, August, 2nd 2018. View Earnings Estimates for CIGNA. What guidance has CIGNA issued on next quarter's earnings? CIGNA issued an update on its FY18 earnings guidance on Thursday, May, 3rd. The company provided EPS guidance of $12.85-13.25 for the period, compared to the Thomson Reuters consensus estimate of $12.78. The company issued revenue guidance of +7-8% to ~$44.53-44.95 billion, compared to the consensus revenue estimate of $44.08 billion. What price target have analysts set for CI? 12 brokers have issued 12 month price targets for CIGNA's stock. Their forecasts range from $190.00 to $255.00. On average, they anticipate CIGNA's share price to reach $218.6667 in the next twelve months. This suggests a possible upside of 26.9% from the stock's current price. View Analyst Ratings for CIGNA. What is the consensus analysts' recommendation for CIGNA? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CIGNA in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." What are Wall Street analysts saying about CIGNA stock? Here are some recent quotes from research analysts about CIGNA stock: 1. According to Zacks Investment Research, "Cigna's shares have outperformed the industry in a year. The company is on track to buy Express Scripts, which should raise its rank in the health insurance industry and equip it better to face competition. Synergies from the acquisition should buoy the company's long-term growth potential. A robust Global Supplemental business, growing Government business, increasing membership, and strong capital position are the other positives. Strong 2018 outlook reflects business strength. The Zacks Consensus Estimate for 2018 earnings has improved in the past 30 days. Increase in leverage, suspension of share buyback and huge execution risk related to the recent deal are the concerns. Its Medicare business is expected to grow less than the industry average. Recently the company has also received negative rating action." (5/28/2018) 2. Jefferies Financial Group Inc analysts commented, "CI reported Q2:17 adjusted EPS of $2.91 (GAAP $3.15), compared to OPCO’s estimate of $2.46 and Street consensus of $2.45. Adjusted results exclude $0.13 of realized investment gains and $0.18 from merger-related tax benefits, offset by $0.07 of amortization expense. The beat was driven by the Healthcare segment, with the Commercial MCR of 78.7% outperforming OPCO/Street estimates by 200/160 bps. Due to the beat, the company raised FY2017 EPS guidance to $9.75-$10.05 vs. $9.35-$9.85, with all three segment outlooks growing by $15-$40M." (8/4/2017) Who are some of CIGNA's key competitors? Some companies that are related to CIGNA include Anthem (ANTM), Aetna (AET), Humana (HUM), Centene (CNC), WellCare Health Plans (WCG), Molina Healthcare (MOH), Trupanion (TRUP) and Advanzeon Solutions (CHCR). Who are CIGNA's key executives? CIGNA's management team includes the folowing people: Mr. David Michael Cordani, Pres, CEO & Director (Age 53)Mr. Eric Paul Palmer, Exec. VP & CFO (Age 41)Ms. Nicole Susan Jones, Exec. VP & Gen. Counsel (Age 47)Mr. Jason D. Sadler, Pres of International Markets (Age 49)Mr. Christopher J. Hocevar, Pres of Strategy, Segments & Solutions (Age 44) Has CIGNA been receiving favorable news coverage? News stories about CI stock have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CIGNA earned a daily sentiment score of 0.15 on Accern's scale. They also gave news stories about the health services provider an impact score of 46.05 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future. Who are CIGNA's major shareholders? CIGNA's stock is owned by a number of of retail and institutional investors. Top institutional investors include Swedbank (0.94%), NN Investment Partners Holdings N.V. (0.47%), Bank of Montreal Can (0.40%), DnB Asset Management AS (0.04%), Fjarde AP Fonden Fourth Swedish National Pension Fund (0.03%) and Xact Kapitalforvaltning AB (0.02%). Company insiders that own CIGNA stock include Alan Muney, Christopher J Hocevar, David Cordani, Donna F Zarcone, Hoeltzel Mary T Agoglia, Isaiah Harris, Jr, Jane E Md Henney, Jason D Sadler, John M Murabito, Lisa R Bacus, Mary T Hoeltzel, Matthew G Manders, Michael W Triplett, Nicole S Jones, Thomas A Mccarthy and William D Zollars. View Institutional Ownership Trends for CIGNA. Which institutional investors are selling CIGNA stock? CI stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Clinton Group Inc., Xact Kapitalforvaltning AB, Fjarde AP Fonden Fourth Swedish National Pension Fund, Cullinan Associates Inc., Gateway Investment Advisers LLC, Cobiz Wealth LLC and First American Trust FSB. Company insiders that have sold CIGNA company stock in the last year include Alan Muney, Christopher J Hocevar, David Cordani, Donna F Zarcone, Hoeltzel Mary T Agoglia, Isaiah Harris, Jr, Jane E Md Henney, Jason D Sadler, John M Murabito, Lisa R Bacus, Mary T Hoeltzel, Matthew G Manders, Michael W Triplett, Nicole S Jones and William D Zollars. View Insider Buying and Selling for CIGNA. Which institutional investors are buying CIGNA stock? CI stock was acquired by a variety of institutional investors in the last quarter, including Swedbank, First National Bank of Omaha, Empowered Funds LLC, NN Investment Partners Holdings N.V., Private Capital Advisors Inc., Polianta Ltd, DnB Asset Management AS and IFM Investors Pty Ltd. View Insider Buying and Selling for CIGNA. How do I buy shares of CIGNA? Shares of CI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is CIGNA's stock price today? One share of CI stock can currently be purchased for approximately $172.35. How big of a company is CIGNA? CIGNA has a market capitalization of $42.11 billion and generates $41.62 billion in revenue each year. The health services provider earns $2.24 billion in net income (profit) each year or $10.46 on an earnings per share basis. CIGNA employs 46,000 workers across the globe. How can I contact CIGNA? CIGNA's mailing address is 900 COTTAGE GROVE ROAD, BLOOMFIELD CT, 06002. The health services provider can be reached via phone at 860-226-6000 or via email at [email protected] MarketBeat Community Rating for CIGNA (NYSE CI)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 608 (Vote Outperform)Underperform Votes: 408 (Vote Underperform)Total Votes: 1,016MarketBeat's community ratings are surveys of what our community members think about CIGNA and other stocks. Vote "Outperform" if you believe CI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/16/2018 by MarketBeat.com StaffFeatured Article: Are Wall Street analysts' stock ratings worth following?